The differences in apoptosis induction and proliferative indices reflect key differences in how normal tissues respond and adapt to RAS inhibition with RMC-6236 compared with tumors driven by mutant KRAS, providing a rational basis for the tumor selectivity of RAS inhibition. The gene discussed is KRAS; the disease is neoplasm.